SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following earnings, with debates over its high P/E ratio and valuation despite revenue beats and raised guidance; Michael Burry's reported short position is fueling bearish sentiment. The community is split, with bulls citing strong growth and AI platform adoption, while bears express concerns about overvaluation and reliance on government contracts.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending as community members express strong bullish sentiment and promote its association with the Solana ecosystem. There is active discussion around community building, long-term vision, and dismissing negative sentiment. The community emphasizes resilience and supporting fellow builders in the crypto space.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies Inc is trending amid fluctuating cryptocurrency values, particularly Ethereum, influencing the stock's movements. The community is actively debating whether the current dip presents a buying opportunity or signals a longer-term downturn, with opinions split on the influence of figures like Tom Lee and potential company actions like share buybacks and staking. Discussions also involve the broader crypto market's reaction to economic factors and regulatory developments.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss recent coverage from Stifel and JPMorgan, highlighting the company's potential in lunar infrastructure and space investments amid rising competition with China. The community is weighing the significance of new contracts and upcoming milestones, including the LTV contract and IM-3 mission, while also debating the stock's volatility and short interest.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin $CAW, also known as crow with knife, is trending as community members express bullish sentiment and encourage others to "buy the dip." Community chatter highlights the token's deflationary nature, multichain functionality, and staking opportunities. Bullish investors see the token as a meme with growing utility.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a sharp decline following confirmatory trial results for its PMO therapies; while the trial missed its primary endpoint, the company highlights COVID-related impacts and plans to discuss a path to traditional approval with the FDA. The community is debating the significance of the trial results, the future of PMO therapies, and the potential impact on the company's valuation, with some viewing the sell-off as an overreaction and a buying opportunity given Sarepta's revenue and pipeline.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to a mixed reaction to earnings, initially dropping on EPS and sales misses despite subscriber growth. The community is debating whether the dip presents a buying opportunity, while analysts are adjusting price targets and highlighting both the potential and the risks around valuation and future growth. Commentary suggests a possible short squeeze is in play, but also concern about overall market weakness affecting SPOT.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a recent EPS beat and increased revenue guidance, tempered by concerns about share price control. The community is also focused on a lawsuit involving a former FDA official and allegations of a revenge campaign against Aurinia's chairman, which has impacted the stock's value. Discussions include potential outcomes of the lawsuit and its broader implications for the company.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber ($UBER) is trending amid mixed sentiment ahead of upcoming earnings, with some investors expecting a strong report and a push towards $105-$110, while others anticipate a flat or negative surprise. Community talking points include potential AI partnerships and the company's growing presence in autonomous vehicle technology, particularly discussions around its partnerships with NVIDIA and Lucid, and the Robotaxi market as a whole. Bullish investors view UBER as undervalued, citing its leading market position and potential for further growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending amid discussions around AI infrastructure buildout and partnerships, including a significant AI supercomputer project with NVIDIA and the Department of Energy. Community chatter also focuses on Oracle's debt levels and potential implications for future growth and profitability. Additionally, speculation continues around the potential TikTok deal and its impact on Oracle's cloud business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.</li><li>The report marks CEO Mike Doustdar’s first since taking charge, with investors watching for guidance on restructuring, job cuts, and strategy following a board overhaul.</li><li>The earnings release comes as Pfizer escalates its legal battle over Novo’s $9 billion bid for Metsera, accusing the company of trying to delay competition in the obesity drug market.</li></ul>Novo Nordisk will report its third-quarter (Q3) results on Wednesday, marking its first earnings release under new CEO Mike Doustdar. Analysts expect weaker profits and slower growth amid intensifying competition from Eli Lilly and mounting legal pressure from Pfizer.The company’s U.S.-listed stock fell 0.7% to close at $49.11 on Monday.<h2 class="st-heading-2">Analysts Expect Softer Quarter</h2>According to Koyfin estimates, analysts expect revenue of $11.87 billion, down 2% year-on-year. EBITDA is projected at $5.28 billion, a 13% decline, while EBIT is forecast to drop 26% to $3.92 billion. GAAP earnings per share (EPS) is seen at $0.70, compared with $0.94 a year earlier.BMO Capital Markets analyst Evan Seigerman said investors will be looking for signs of how Novo plans to get past restructuring and reignite obesity growth, after multiple guidance cuts this year, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ceo-faces-baptism-fire-amid-board-shakeup-pfizer-fight-2025-11-04/">report</a>.&nbsp;Jefferies analyst Michael Leuchten noted that Novo remains heavily dependent on semaglutide, the active ingredient in Wegovy and Ozempic, which underpins roughly 60% of future revenues. “It looks like the obesity market in the U.S. is running out of steam, and we don’t fully understand why,” Leuchten said, pointing to underwhelming new-patient starts.<h2 class="st-heading-2">Leadership Transition And Legal Uncertainty</h2>The report will also be the first under CEO Mike Doustdar, who took over in August after the Novo Nordisk Foundation, the company’s controlling shareholder, overhauled the board, replacing six independent directors. Former CEO Lars Rebien Sorensen is set to return as chairman following the Nov. 14 shareholder meeting.Paul Major, healthcare portfolio manager at Bellevue Asset Management, said the tone Doustdar sets on the company’s future strategy will be a point of focus, adding that investors are watching for alignment between management and the Foundation on Novo’s turnaround plan.<h2 class="st-heading-2">Pfizer Legal Dispute Adds Pressure</h2>The quarter also comes as Pfizer escalates its legal challenge over Novo’s $9 billion rival bid for Metsera, a U.S. biotech developing next-generation obesity drugs. Pfizer alleged that the Danish drugmaker structured the deal to delay competition and preserve market share for Wegovy and Ozempic.Novo has denied the claims, calling them “absurd” and arguing that it would accelerate Metsera’s commercialization if the claims were successful. The case will be heard on Tuesday.TD Cowen analyst Michael Nedelcovych said he will watch for any insights on the Metsera bid and whether Doustdar signals an appetite for further acquisitions.<h2 class="st-heading-2">Stocktwits Bulls View Novo’s Dip As A Buying Opportunity</h2>On Stocktwits, retail sentiment for both Novo Nordisk and Pfizer was ‘bullish’ amid ‘ high’ message volumes.One user commented that Novo Nordisk’s aggressive $6.5 billion bid for Metsera made it the biggest risk-taker in the dispute with Pfizer, adding that Metsera stood to benefit either way, while Pfizer faced litigation setbacks.<stembedurl>https://stocktwits.com/dyrtydave/message/634800076</stembedurl>Another said investors were overreacting to Novo’s share decline, describing it as a strong global company expanding its pipeline and calling the dip a potential buying opportunity.<stembedurl>https://stocktwits.com/Prit89/message/634764720</stembedurl><a href="https://stocktwits.com/Prit89/message/634764720">Novo Nordisk’s U.S.-listed stock</a> has declined 42% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies.

Equity

Pfizer plays hardball in weight-loss drug fight

Pfizer has filed two lawsuits to block Novo Nordisk's $9bn bid to buy Metsera...

<ul class="summary-bullets"><li>Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.</li><li>Subscriber count grew 21% to almost 2.5 million, with monthly online revenue per subscriber up 19% to $80.</li><li>On Stocktwits, retail sentiment was ‘extremely bullish,’ with users predicting the stock could climb toward $50 once Novo Nordisk partnership talks conclude.</li></ul>Shares of Hims &amp; Hers Health rose about 5% in after-hours trading on Monday after the company reported another quarter of strong growth and said it’s in talks with Novo Nordisk to bring&nbsp;weight-loss drug Wegovy to its platform.<h2 class="st-heading-2">Revenue And Subscriber Growth Remain Strong</h2>Revenue rose 49% from a year earlier to $599 million as strength continued across the company’s weight-loss and wellness businesses. Net income was $15.8 million, versus $75.6 million a year ago, which had reflected a one-time tax benefit. Adjusted EBITDA increased 53% to $78.4 million.Hims &amp; Hers now has nearly 2.5 million subscribers, up 21% from a year earlier, and monthly revenue per subscriber has also risen 19% to $80. Cash from operations soared to $149 million, while free cash flow for the quarter remained stable at $79 million.Gross margin fell to 74%, from 79% a year earlier, mainly due to changes in shipping cadence and higher production costs related to Hims &amp; Hers’ growing weight-loss portfolio.<h2 class="st-heading-2">Talks With Novo Nordisk</h2>The company said it’s in active talks with Novo Nordisk to make Wegovy injections and an eventual oral formulation available on its platform once they have prescribing approval. No agreement has been reached, and the company said that a deal is not guaranteed.The company said during the earnings call that it expects to bring in over $725 million in weight-loss revenue this year, and that it’s spending money to build new sterile compounding and fulfillment centers to keep up with the surge in demand.<h2 class="st-heading-2">Outlook For 2025</h2>Hims &amp; Hers narrowed its 2025 revenue forecast to a range of $2.335 billion to $2.355 billion, slightly above its previous estimate of $2.3 billion to $2.4 billion. It now expects adjusted EBITDA between $307 million and $317 million, compared with the earlier range of $295 million to $335 million.For the fourth quarter, the company expects revenue of $605 million to $625 million and adjusted EBITDA of $55 million to $65 million. The company said near-term margins will be affected by ongoing investments in its compounding operations and by price adjustments to GLP-1 drugs, though it expects conditions to improve next year as volumes continue to rise.<h2 class="st-heading-2">Stocktwits Traders Bet On Further Gains</h2>On Stocktwits, retail sentiment for Hims was ‘extremely bullish’ amid a 1,734% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/135;" src="https://news.stocktwits-cdn.com/hims_ss_jpg_d349536f51.webp" alt="hims ss.jpg" width="968" height="135"><figcaption>HIMS sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed the stock as a solid buy for the next move higher, expecting it to stay above the $30 range.&nbsp;<stembedurl>https://stocktwits.com/Lucy888/message/634788120</stembedurl>Another predicted that shares could climb toward $50 following the company’s strong results and new initiatives. Meanwhile, a third user said the stock could rally sharply once its ongoing discussions with Novo Nordisk are concluded.<stembedurl>https://stocktwits.com/bestest1/message/634776299</stembedurl><stembedurl>https://stocktwits.com/Maximusprofit/message/634778175</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers Health’s stock</a> has risen 84% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a HIMS logo is displayed on a smartphone. (Photo Illustration by Avishek Das/SOPA Images/LightRocket via Getty Images)

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market...

<ul class="summary-bullets"><li>The new lawsuit alleges that Novo Nordisk’s proposed transaction violates several laws due to the anticompetitive effects it would have on the GLP-1 drug market.</li><li>It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.</li><li>Pfizer added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward. &nbsp;</li></ul>Pfizer Inc. (PFE) on Monday announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.The lawsuit alleges that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action by the company to protect its dominant market position in GLP-1 drugs by capturing and killing a nascent American competitor before it gains the support of Pfizer.<h2 class="st-heading-2">What Does The New Lawsuit Say?</h2>The new lawsuit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251102755714/en/Pfizer-Files-Federal-Antitrust-Claims-in-Second-Lawsuit-Against-Metsera-its-Controlling-Stockholders-and-Novo-Nordisk">alleges</a> that Novo Nordisk’s proposed transaction violates several laws because of the anticompetitive effects it would have in the GLP-1 drug markets and negatively impact patients who suffer from obesity, diabetes, and other metabolic conditions. It further argues that Metsera’s controlling stockholders, including Validae Health, L.P., and Population Health Partners GP, have conspired with Metsera and Novo Nordisk to further these anticompetitive activities.Pfizer further added that it intends to seek all appropriate remedies, including injunctive relief, to ensure that Novo Nordisk’s proposed transaction is not permitted to move forward.“Metsera’s and its controlling stockholders’ actions, as well as those of Novo Nordisk, are in clear violation of the antitrust laws. We are confident in the merits of our case and look forward to presenting it to the Court,” the company said.Pfizer also filed a separate lawsuit last week against Metsera, its Board of Directors, and Novo Nordisk in the Delaware Court of Chancery, asserting claims for breach of contract and fiduciary duty. It has also filed a motion with the Court of Chancery requesting that it issue a temporary restraining order to block Metsera from terminating the merger agreement with itself. &nbsp;<h2 class="st-heading-2">What Sparked The Legal Battle?</h2>Danish drugmaker Novo Nordisk (NVO) announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) <a href="https://stocktwits.com/news-articles/markets/equity/metsera-stock-surges-pre-market-after-pfizer-confirms-acquisition/chDQNVhR3cy">agreement</a> to acquire the smaller obesity biopharmaceutical company in September.Metsera subsequently gave Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.Pfizer, however, maintains that Novo's offer cannot be considered a superior proposal, given the significant regulatory risk, among other factors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MTSR">MTSR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.MTSR stock has more than doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/serina-therapeutics-stock-slumps-premarket-after-fda-place-hold-on-application-to-initiate-clinical-trials-for-experimental-therapy/cL2NcnCR3zB">Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit 

Pfizer filed the lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S, alleging that Novo Nordisk’s recent proposal to acquire Metsera constitutes an anticompetitive action. 

MIKE DAVIS: Foreign weight-loss drugmaker seeks fat profits by gobbling up American upstart

'Something is rotten in the state of Denmark,' as Hamlet said in Shakespeare's time. It was true then, and it's true today.While Senate Democrats are holding our government hostage to their...

Global week ahead: Is Novo Nordisk past 'peak uncertainty'?

CNBC's Charlotte Reed will travel to Copenhagen to speak with Novo Nordisk's new CEO after a bumpy few months...

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.76	--	--	N/A
Q2 '25	$0.92	$0.93	1.42%	BEAT
Q1 '25	$0.91	$0.99	9.16%	BEAT
Q4 '24	$0.83	$0.89	6.80%	BEAT
Q3 '24	$0.88	$0.88	0.19%	BEAT

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest NVO News

NVONovo Nordisk A/S